T his issue of Pediatric Annals is the final one to appear both in print and electronically, as the journal is transitioning to an all online format in January. From my older person's perspective, this is unfortunate but certainly in keeping with current trends in the publishing business. Other changes will be occurring also, including discontinuing Case Challenges as well as the "Firm Rounds" column.
I want to acknowledge Dr. Bob Listernick's outstanding job of editing the "Firm Rounds" column over the past 15 years (180 Firm Rounds!). The column in this issue is the final "Firm Rounds" to be published in this journal. We trust that these discussions have been useful; we know they have been extremely educational and even entertaining. Bob, job superbly done!
The important topic of sudden cardiac death in the child and adolescent is the focus of this issue of Pediatric Annals. Dr. Stuart Berger of the University of California Davis has coordinated the excellent articles that discuss palpitations and arrhythmias, chest pain in children, syncope, and the prevention of sudden cardiac death.
THE SUPPORT CASE DECISION
Therapeutic advances generally occur as a consequence of well-designed randomized trials, with appropriate informed consent of participants/parents/ guardians. An important recent court decision is particularly instructive to those of us who care for children and who participate in clinical research studies; it's also important to the patients who benefit from these studies.
In the SUPPORT study (Surfactant, Positive Pressure, and Oxygenation
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Editorial standard of care when the study was performed (2004) (2005) (2006) (2007) (2008) (2009) . The purpose of the study was to assess whether the risk of retinopathy of prematurity (ROP) due to oxygen therapy could be minimized. 1 The study found a lower risk of ROP in the lower O 2 saturation range group but also that there was an unexpected lower survival rate in that lower O 2 group. The study had been designed by an international neonatology research consortium, was reviewed and funded by NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development) of the National Institutes of Health, and was approved by Institutional Review Boards (IRB) at all 23 study sites. 2 In 2013, 3 to 4 years after the trial was completed and after the results were published in the New England Journal of Medicine, 1 the federal Office for Human Research Protection informed the principal study site at the University of Alabama-Birmingham that the study consent forms were inadequate because they did not inform parents of "reasonably foreseeable risks." This eventually led to a class action lawsuit filed by parents of participating infants who claimed that their babies had suffered serious injuries as a consequence of participating in the study. The defendants in the lawsuit were the members of the primary site IRB, the principal investigator Dr. Waldemar Carlo, and the manufacturer of the pulse oximeter used in the study. 2, 3 In August 2015, Karen O. Bowdre, Chief Judge of the US District Court for the Northern District of Alabama, summarily dismissed the lawsuit without trial-an important victory for everyone who designs and participates in enrolling patients in clinical trials to improve medical care. 3 Judge Bowdre rejected the plaintiff's argument that because infants participated in the SUPPORT study and some extremely low-birth-weight infants experienced medical problems, it therefore could be concluded that their participation in the study caused those problems. The judge clearly recognized that extreme prematurity and its complications placed babies at very high risk of ROP and neurologic sequelae and risk of death. As stated in a recent New England Journal of Medicine editorial on this topic, "When people contract an illness, there is a risk that bad things will happen. Research undertaken to improve the care of people stricken with such an illness cannot be expected to eliminate that intrinsic risk." 4 Additionally, it is clear that it is unethical and inappropriate to review and criticize the design of a clinical trial and its consent form retrospectively only after taking into account the new knowledge gained from carrying out that research study. This summary judgment serves as a clear vindication of our field's system of oversight of clinical research and of the investigators who organized and executed this important study.
THIS MONTH'S STAMPS
Perhaps the most surprising stamp is the 2015 stamp from Slovakia (Slovensko) issued to celebrate the 20th anniversary of that country's only pediatric bone marrow transplant center. In Bratislava more than 320 transplants have been performed, twothirds for malignancies. 
